CSIMarket
 


Eli Lilly And Company  (LLY)
Other Ticker:  
 
 

LLY's Capital Expenditures Growth by Quarter and Year

Eli Lilly And's Capital Expenditures results by quarter and year




LLY Capital Expenditures (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 454.70 326.50 394.30
III Quarter September - 393.10 263.40 269.80
II Quarter June - 281.80 240.30 310.00
I Quarter March 300.30 258.30 203.70 236.50
FY   300.30 1,387.90 1,033.90 1,210.60



LLY Capital Expenditures first quarter 2021 Y/Y Growth Comment
Eli Lilly And Company achieved in the first quarter, above Company average Capital Expenditures increase of 16.26% year on year, to $ 300.30 millions.

Looking into first quarter results within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Capital Expenditures growth. While Eli Lilly And Company' s Capital Expenditures growth of 16.26% ranks overall at the positon no. 644 in the first quarter.




LLY Capital Expenditures ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 39.26 % -17.2 % -11.09 %
III Quarter September - 49.24 % -2.37 % 11.17 %
II Quarter June - 17.27 % -22.48 % 39.89 %
I Quarter March 16.26 % 26.8 % -13.87 % 39.94 %
FY   - 34.24 % -14.6 % 12.43 %

Financial Statements
Eli Lilly And's first quarter 2021 Capital Expenditures $ 300.30 millions LLY's Income Statement
Eli Lilly And's first quarter 2020 Capital Expenditures $ 258.30 millions Quarterly LLY's Income Statement
New: More LLY's historic Capital Expenditures Growth >>


LLY Capital Expenditures (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 15.67 % 23.96 % 46.15 %
III Quarter September - 39.5 % 9.61 % -12.97 %
II Quarter June - 9.1 % 17.97 % 31.08 %
I Quarter March -33.96 % -20.89 % -48.34 % -46.67 %
FY (Year on Year)   - 34.24 % -14.6 % 12.43 %




Capital Expenditures first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #134
Overall #644

Capital Expenditures Y/Y Growth Statistics
High Average Low
131.05 % 5.22 % -66.84 %
(Sep 30 2015)   (Sep 30 2016)
Capital Expenditures first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #134
Overall #644
Capital Expenditures Y/Y Growth Statistics
High Average Low
131.05 % 5.22 % -66.84 %
(Sep 30 2015)   (Sep 30 2016)

Capital Expenditures by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Eli Lilly And's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
206.39 % 23.67 % -85.4 %
(Sep 30 2015)  


LLY's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2021 Eli Lilly And Company disclosed fall in Capital Expenditures from the previous quarter by -33.96% to $ 300.30 millions, from $ 454.70 millions released in the previous quarter.

When you analyse present slump in the quarter, you suppose to presume, that usually I. Quarter Capital Expenditures appear to be softer in contrast to the preciding period

Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Eli Lilly And's Capital Expenditures growth quarter on quarter, overall rank is 433.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #52
Overall #433
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #52
Overall #433
Capital Expenditures Q/Q Growth Statistics
High Average Low
206.39 % 23.67 % -85.4 %
(Sep 30 2015)  


LLY's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2021 Eli Lilly And Company realized fall in Capital Expenditures from the previous quarter by -33.96% to $ 300.30 millions, from $ 454.70 millions released a quarter before.

This is not huge issue, as I. Quarter Capital Expenditures frequently tend to plunge in the I. Quarter Isabelle W. Young, Healthcare sector contributor located in Houston told.

Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Eli Lilly And's Capital Expenditures growth quarter on quarter, overall rank is 433.


Eli Lilly And's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
Cumulative Capital Expenditures 12 Months Ending $ 1,429.90 $ 1,387.90 $ 1,259.70 $ 1,130.00 $ 1,088.50
Y / Y Capital Expenditures Growth (TTM) 31.36 % 34.24 % 14.34 % 1.98 % -7.58 %
Year on Year Capital Expenditures Growth Overall Ranking # 118 # 603 # 152 # 1287 # 1710
Seqeuential Capital Expenditures Change (TTM) 3.03 % 10.18 % 11.48 % 3.81 % 5.28 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 259 # 769 # 96 # 880 # 957




Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Mar 31 2021 period, Eli Lilly And's cumulative twelve months Capital Expenditures were $ 1,430 millions, company would post below average annual Capital Expenditures growth of 5.28% year on year, if the fiscal year would end at Mar 31 2021.
A slow-down in the Eli Lilly And's Capital Expenditures growth from the 454.7% growth in Dec 31 2020.

Among companies within the Healthcare sector 18 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 118, from total ranking in previous quarter at 603.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1495.62 %
45.88 %
-80.2 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 11
Healthcare Sector # 19
Overall # 118

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1955.54 %
79.92 %
-86.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 37
S&P 500 # 259
Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Mar 31 2021 period, Eli Lilly And's cumulative twelve months Capital Expenditures were $ 1,430 millions, company would post below average annual Capital Expenditures growth of -86.89% year on year, if the fiscal year would end at Mar 31 2021.
A slow-down in the Eli Lilly And's Capital Expenditures growth from the 454.7% growth in Dec 31 2020.

Among companies within the Healthcare sector 18 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 118, from total ranking in previous quarter at 603.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1495.62 %
45.88 %
-80.2 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 11
Healthcare Sector # 19
Overall # 118

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1955.54 %
79.92 %
-86.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 37
S&P 500 # 259




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
LLY's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for LLY's Competitors
Capital Expenditures Growth for Eli Lilly And's Suppliers
Capital Expenditures Growth for LLY's Customers

You may also want to know
LLY's Annual Growth Rates LLY's Profitability Ratios LLY's Asset Turnover Ratio LLY's Dividend Growth
LLY's Roe LLY's Valuation Ratios LLY's Financial Strength Ratios LLY's Dividend Payout Ratio
LLY's Roa LLY's Inventory Turnover Ratio LLY's Growth Rates LLY's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2021
Tabula Rasa Healthcare inc 27.93%$ 27.930 millions
Novocure Limited27.92%$ 27.924 millions
Elanco Animal Health Inc26.13%$ 26.126 millions
Harvard Bioscience Inc24.90%$ 24.896 millions
Heska Corporation24.76%$ 24.762 millions
Magellan Health inc 24.31%$ 24.308 millions
Adma Biologics Inc 23.92%$ 23.919 millions
Irhythm Technologies Inc 23.67%$ 23.671 millions
Surgery Partners Inc 22.88%$ 22.881 millions
Lemaitre Vascular Inc22.71%$ 22.711 millions
Incyte Corp22.46%$ 22.458 millions
Insulet Corporation21.90%$ 21.898 millions
Avantor Inc 19.84%$ 19.841 millions
Keros Therapeutics Inc 19.32%$ 19.318 millions
Cytosorbents Corporation19.23%$ 19.227 millions
Encompass Health Corporation18.32%$ 18.323 millions
Covetrus Inc 18.18%$ 18.182 millions
Protara Therapeutics Inc 17.41%$ 17.408 millions
Thermogenesis Holdings Inc 17.39%$ 17.391 millions
Teva Pharmaceutical Industries Ltd17.19%$ 17.188 millions
Dentsply Sirona Inc 17.19%$ 17.188 millions
Medpace Holdings inc 17.01%$ 17.011 millions
Amgen Inc 16.90%$ 16.901 millions
Organogenesis Holdings Inc 16.83%$ 16.828 millions
Ultragenyx Pharmaceutical Inc 16.44%$ 16.444 millions
Eli Lilly And Company16.26%$ 16.260 millions
Owens and Minor Inc 15.93%$ 15.929 millions
Establishment Labs Holdings Inc 15.70%$ 15.701 millions
Acadia Pharmaceuticals Inc 15.20%$ 15.203 millions
Merck and Co Inc 15.01%$ 15.010 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ASLE's Profile

Stock Price

ASLE's Financials

Business Description

Fundamentals

Charts & Quotes

ASLE's News

Suppliers

ASLE's Competitors

Customers & Markets

Economic Indicators

ASLE's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071